- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06102200
Opioid Variations and Effects: Recovery Coach OUD Medications and Evidence-based Therapy (OVERCOME2)
An Integrated Intervention Involving Recovery Coaching and Cognitive Behavioral Therapy for Opioid Use Disorder
The Overcome II study is a randomized controlled trial among adults receiving sublingual buprenorphine to help prevent or reduce illicit drug use. The study outcomes will be compared between three treatment arms: (1) sublingual buprenorphine only, which is the standard-of-treatment (2) sublingual buprenorphine with a computer-based cognitive behavior therapy for substance use disorders (CBT4CBT), (3) sublingual buprenorphine with CBT4CBT and peer recovery coaching. The primary outcome of interest is the reduction in the proportion of positive results for saliva toxicology screenings for any drug during the 8-week treatment period. Study participants will also be assessed for the outcomes of retention to standard-of-treatment and illicit drug use at 1-, 3-, and 6-months follow-ups after the end of treatment.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Buprenorphine has proven to be an effective pharmacologic strategy for treating OUD. However, buprenorphine is unlikely to give greater overall protection because of the shorter duration of treatment. There is a need for studies on interventions that could increase retention to buprenorphine, especially among those with ongoing illicit substance and polysubstance use.
Using a randomized controlled trial study design, the Overcome II study aims to investigate the incremental benefit in terms of reduction in illicit drug use and retention in standard of treatment due to providing the peer recovery coach and/or CBT4CBT interventions as a compliment to standard-of-treatment among persons receiving medication for opioid use. The study outcomes will be compared between three treatment arms: (1) sublingual buprenorphine only, which is the standard-of-treatment (2) sublingual buprenorphine with CBT4CBT, (3) sublingual buprenorphine with CBT4CBT and peer recovery coaching. The primary outcome of interest is reduction in the proportion of positive results for saliva toxicology screenings for any drug during the 8-week treatment period. Study participants will also be assessed for the outcomes of retention to standard-of-treatment and illicit drug use at 1-, 3-, and 6-months follow-ups after the end of treatment. The institutional review board at Prisma Health will provide the oversight for the ethical conduct of the study. Potential participants at Prisma Health will be screened for eligibility, will undergo the informed consent procedure, and eligible persons who consent to participation will be recruited into the study.
The participants will be randomized of one of the three treatment arms in a 1:1:1 ratio. The study will aim to recruit 30 participants per treatment arm. Study procedures will be conducted both virtually and at research facilities of the Prisma Health Addiction Medicine Center, in Greenville, SC. Participants will attend the research visits once a week during the first eight weeks (sessions 1 to 8), and 1-, 3-, and 6- months after the end of treatment.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
South Carolina
-
Greenville, South Carolina, Forente stater, 29605
- Greenville Health System
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults (≥18 years of age);
- DSM-V diagnosis of OUD, confirmed via electronic medical record review;
- Currently receiving SL buprenorphine/ naloxone and/or buprenorphine HCL;
- Initiated SL buprenorphine within the last 30 days;
- Willing to accept a random assignment to either treatment arm:
- Adequate computer skills
Exclusion Criteria:
- Severe medical or psychiatric disability that could impair the ability to perform study related activities (determined by the clinician);
- Pregnancy, planning conception, or breast-feeding for female participants;
- Inability to independently read and/or comprehend the consent form or other study materials;
- Inability to read/speak English (inability to independently read and comprehend the consent form or other study materials);
- Current suicidal ideation based on the Patient Health Questionnaire-9
- Have taken or received any prescribed buprenorphine product within 30 days prior to the current treatment episode.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Standard of care
Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits. |
Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits. |
|
Eksperimentell: Standard of care + CBT4CBT
This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise. |
This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
Andre navn:
|
|
Eksperimentell: Standard of care + CBT4CBT+ RC
This condition will integrate the standard of care, CBT4CBT, and recovery coaching services with Assertive Community Engagement (ACE) model interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support. |
This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
Andre navn:
Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Drug Use
Tidsramme: 8 weeks
|
The percentage of of saliva toxicology screens positive for all drugs during the 8 initial study weeks |
8 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants Retained to Buprenorphine at 3 Months
Tidsramme: 3 months post-treatment follow up at 20 weeks
|
Retention to buprenorphine |
3 months post-treatment follow up at 20 weeks
|
|
Number of Participants Retained to Buprenorphine at 6 Months
Tidsramme: 3 months post-treatment follow up at 32 weeks
|
Retention to buprenorphine |
3 months post-treatment follow up at 32 weeks
|
|
Drug Use
Tidsramme: Percentage of positive saliva toxicology screens at 12 week mark
|
The percentage of saliva toxicology screens positive for all drugs at 1 month follow-up |
Percentage of positive saliva toxicology screens at 12 week mark
|
|
Drug Use
Tidsramme: Percentage of positive saliva toxicology screens at 20 week mark
|
The percentage of saliva toxicology screens positive for all drugs at 3 month follow-up |
Percentage of positive saliva toxicology screens at 20 week mark
|
|
Drug Use
Tidsramme: Percentage of positive saliva toxicology screens at 32 week mark
|
The percentage of saliva toxicology screens positive for all drugs at 6 month follow-up |
Percentage of positive saliva toxicology screens at 32 week mark
|
|
Opioid Use
Tidsramme: Percentage of opioid positive saliva toxicology screens at during first 8 weeks of study participation
|
The percentage of saliva toxicology screens positive for opioids during the 8 initial study weeks |
Percentage of opioid positive saliva toxicology screens at during first 8 weeks of study participation
|
|
Opioid Use
Tidsramme: Percentage of opioid positive saliva toxicology screens at 12 week mark
|
The percentage of saliva toxicology screens positive for opioids at 1 month follow-up |
Percentage of opioid positive saliva toxicology screens at 12 week mark
|
|
Opioid Use
Tidsramme: Percentage of opioid positive saliva toxicology screens at 20 week mark
|
The percentage of saliva toxicology screens positive for opioids at 3- month follow-up |
Percentage of opioid positive saliva toxicology screens at 20 week mark
|
|
Opioid Use
Tidsramme: Percentage of opioid positive saliva toxicology screens at 32 week mark
|
The percentage of saliva toxicology screens positive for opioids at 6- month follow-up |
Percentage of opioid positive saliva toxicology screens at 32 week mark
|
|
Positive Self-report Drug Use
Tidsramme: Self-reported drug use in the last 30 days, captured at 8 week mark
|
Self-report drug use in the past 30 days |
Self-reported drug use in the last 30 days, captured at 8 week mark
|
|
Positive Self-report Drug Use
Tidsramme: Self-reported drug use in the last 30 days, captured at 12 week mark
|
Self-report drug use in the past 30 days |
Self-reported drug use in the last 30 days, captured at 12 week mark
|
|
Positive Self-report Drug Use
Tidsramme: Self-reported drug use in the last 30 days, captured at 20 week mark
|
Self-report drug use in the past 30 days |
Self-reported drug use in the last 30 days, captured at 20 week mark
|
|
Positive Self-report Drug Use
Tidsramme: Self-reported drug use in the last 30 days, captured at 32 week mark
|
Self-report drug use in the past 30 days |
Self-reported drug use in the last 30 days, captured at 32 week mark
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Alain H Litwin, MD, Prisma Health
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Pericot-Valverde I, Perez A, Heo M, Coleman A, Ortiz E, Merchant K, Melling T, Litwin A. Rationale, design, and methodology of a randomized pilot trial of an integrated intervention combining computerized behavioral therapy and recovery coaching for people with opioid use disorder: The OVERCOME study. Contemp Clin Trials Commun. 2022 May 5;28:100918. doi: 10.1016/j.conctc.2022.100918. eCollection 2022 Aug.
- Pericot-Valverde I, Heo M, Byrne KA, Karasz A, Perez A, Lopes S, Groome M, Voss S, King A, Barnick K, Litwin AH. Rationale and design of a three-arm randomized clinical trial to improve drug use and retention in care of people with opioid use disorder on buprenorphine: OVERCOME II study. Contemp Clin Trials. 2026 Mar;162:108226. doi: 10.1016/j.cct.2026.108226. Epub 2026 Jan 17.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1930664-6
- R34DA057662 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .